The instruction for medical use
of TOKSIVENOL medicine
the Trade name
Toksivenol
Mezhdunarodnoye the unlicensed name
Is not present
the Dosage form
of the Tablet, coated, 300 mg / 3 mg
Structure
One tablet contains
active agents: trokserutin 300 mg
carboazochrome of 3 mg,
excipients: the Arabian gum, starch corn, the talc purified, povidone, silicon dioxide colloidal, magnesium stearate,
structure of a cover: titan dioxide (E171), calcium carbonate, kaolin, dye orange-yellow S (E 110), dye indigotin (E132) (sodium indigodisulfonat), sucrose.
The description
Round biconvex tablets, coated, bezhevato – pink color.
Pharmacotherapeutic group
Vasoprotectives. The drugs reducing permeability of capillaries.
Bioflavonoids.
The code of automatic telephone exchange C05CA54
the Pharmacological
Pharmacokinetics Later properties of intake trokserutin is quickly put from a digestive tract. The maximum concentration (Cmax) of a trokserutin in blood plasma is reached in 1 hour and makes 81.00 ± 2.94 ng/ml, the period of biological half-decay (T0.5) – 8, 73 ± 0.88 hour.
Linking with plasma proteins makes about 30%. It is metabolized in a liver to aglyukogonny forms mono - di – and trigidroksietilrutozid, glyukurinid and derivatives of arylacetic acid. Elimination half-life varies of 10 - 25 o'clock. About 25%, with bile – about 70% are allocated with urine.
Concentration of carboazochrome in blood plasma is found in 10 min. after use, average peak concentration in blood plasma (Cmax) makes 21.0 ±8.4 ng/ml, and time of achievement of peak of Tmax is 1.2±0.5 h. Elimination half-life T1/2, the average time of keeping (ATK) and the area under a curve of dependence of concentration from time from 2 h to 8 h makes 2.5 ± 0.9 h, 4.1 ± 1.1 h and 65.9 ±25.3 h ng/m, respectively.
The pharmacodynamics
the Optimum combination of the making components of a trokserutin and carboazochrome causes high pharmacological efficiency of drug that will allow to carry out purposefully treatment of vascular diseases and syndromes of bleeding at the increased weakness of capillaries.
Trokserutin possesses P – vitamin activity, shows the significant angioprotektorny properties, restores the broken permeability of capillary vessels, reduces fragility of capillaries, provides their elasticity, elasticity and resistance to traumatic damages.
The pharmacological effect of drug causes strengthening of effect of the vitamin C performing protective function of permeability of a membrane and suppression of a gialuron who, being activated, produces hyaluronic acid – the mucopolysaccharide which is responsible for density of walls of vessels. Besides, decrease release of a histamine, substance vasodilating and causing hypostasis is observed.
Karbazokhr – orthoquinone, a product of oxidation of adrenaline without sympathomimetic activity because of an otsustviye of minor amine group and group about – biphenol. Vasoconstrictive local action on small vessels of the bleeding zone influences reduction of duration of bleeding. This phenomenon occurs without increase in arterial blood pressure and influence on warm activity. It is revealed that carboazochrome explicitly influences durability and permeability of capillaries and also a tone and the reducing force of vessels.
Indications
- chronic venous insufficiency, a varicosity, superficial thrombophlebitis, a periphlebitis, posttraumatic hypostasis,
hematomas, trophic
- the hemorrhoidal
Route of administration nodes and doses
Accept disturbance at chronic venous insufficiency (dermatitis, trophic ulcers) inside at meal time.
In an initiation of treatment accept on 1 tablet 2-3 times a day. Painful symptoms usually pass through 2 weeks. It is recommended to support this dosage before total disappearance of symptoms.
The supporting treatment: on 1 tablet a day within 3-4 weeks.
The daily dose makes 600 mg (on 1 tablet 2 times a day).
The maximum daily dose makes 900 mg (on 1 tablet 3 times a day).
Side effects
- nausea
- urticaria
- face reddening
- a headache
- swelling and an abdominal pain
of the Contraindication
- hypersensitivity to drug components
- a peptic ulcer of a stomach and duodenum, chronic
gastritis (in an aggravation phase)
- children's and teenage age up to 18 years
- pregnancy and the period of a lactation
Medicinal interactions
Strengthens effect of ascorbic acid on structure and permeability of a vascular wall.
Special indications
of Feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
Considering side effects of medicine it is necessary to be careful when driving or potentially dangerous mechanisms.
Overdose
Symptoms - strengthening of side effects of drug.
Treatment is symptomatic.
A form of release and packing
On 10 tablets in blister strip packaging from a film of polyvinylchloride and aluminum foil.
On the 3rd blister strip packagings together with the instruction for medical use on state and Russian place in a pack from cardboard.
To Store storage conditions in the dry place, at a temperature not above 25ºС.
To store out of children's reach.
Not to apply a period of storage of 5 years after an expiration date.
Prescription status
According to the prescription
the Producer
the Owner of a trademark and the certificate of registration is
the ROTAFARM company, Great Britain
KLEVA S.A Is made., Parnitos 189 Ave., 13671 Athens, Greece
According to the license AKARPIA of Servikos Pharmatseutikos of LDA, Portugal.
The address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products
of RK, Almaty, Turksibsky district, Suyunbaya Ave., 222b
Ph. / fax: 8 (7272) 529090
www.worldmedicine.kz
of TOKSIVENOL medicine
the Trade name
Toksivenol
Mezhdunarodnoye the unlicensed name
Is not present
the Dosage form
of the Tablet, coated, 300 mg / 3 mg
Structure
One tablet contains
active agents: trokserutin 300 mg
carboazochrome of 3 mg,
excipients: the Arabian gum, starch corn, the talc purified, povidone, silicon dioxide colloidal, magnesium stearate,
structure of a cover: titan dioxide (E171), calcium carbonate, kaolin, dye orange-yellow S (E 110), dye indigotin (E132) (sodium indigodisulfonat), sucrose.
The description
Round biconvex tablets, coated, bezhevato – pink color.
Pharmacotherapeutic group
Vasoprotectives. The drugs reducing permeability of capillaries.
Bioflavonoids.
The code of automatic telephone exchange C05CA54
the Pharmacological
Pharmacokinetics Later properties of intake trokserutin is quickly put from a digestive tract. The maximum concentration (Cmax) of a trokserutin in blood plasma is reached in 1 hour and makes 81.00 ± 2.94 ng/ml, the period of biological half-decay (T0.5) – 8, 73 ± 0.88 hour.
Linking with plasma proteins makes about 30%. It is metabolized in a liver to aglyukogonny forms mono - di – and trigidroksietilrutozid, glyukurinid and derivatives of arylacetic acid. Elimination half-life varies of 10 - 25 o'clock. About 25%, with bile – about 70% are allocated with urine.
Concentration of carboazochrome in blood plasma is found in 10 min. after use, average peak concentration in blood plasma (Cmax) makes 21.0 ±8.4 ng/ml, and time of achievement of peak of Tmax is 1.2±0.5 h. Elimination half-life T1/2, the average time of keeping (ATK) and the area under a curve of dependence of concentration from time from 2 h to 8 h makes 2.5 ± 0.9 h, 4.1 ± 1.1 h and 65.9 ±25.3 h ng/m, respectively.
The pharmacodynamics
the Optimum combination of the making components of a trokserutin and carboazochrome causes high pharmacological efficiency of drug that will allow to carry out purposefully treatment of vascular diseases and syndromes of bleeding at the increased weakness of capillaries.
Trokserutin possesses P – vitamin activity, shows the significant angioprotektorny properties, restores the broken permeability of capillary vessels, reduces fragility of capillaries, provides their elasticity, elasticity and resistance to traumatic damages.
The pharmacological effect of drug causes strengthening of effect of the vitamin C performing protective function of permeability of a membrane and suppression of a gialuron who, being activated, produces hyaluronic acid – the mucopolysaccharide which is responsible for density of walls of vessels. Besides, decrease release of a histamine, substance vasodilating and causing hypostasis is observed.
Karbazokhr – orthoquinone, a product of oxidation of adrenaline without sympathomimetic activity because of an otsustviye of minor amine group and group about – biphenol. Vasoconstrictive local action on small vessels of the bleeding zone influences reduction of duration of bleeding. This phenomenon occurs without increase in arterial blood pressure and influence on warm activity. It is revealed that carboazochrome explicitly influences durability and permeability of capillaries and also a tone and the reducing force of vessels.
Indications
- chronic venous insufficiency, a varicosity, superficial thrombophlebitis, a periphlebitis, posttraumatic hypostasis,
hematomas, trophic
- the hemorrhoidal
Route of administration nodes and doses
Accept disturbance at chronic venous insufficiency (dermatitis, trophic ulcers) inside at meal time.
In an initiation of treatment accept on 1 tablet 2-3 times a day. Painful symptoms usually pass through 2 weeks. It is recommended to support this dosage before total disappearance of symptoms.
The supporting treatment: on 1 tablet a day within 3-4 weeks.
The daily dose makes 600 mg (on 1 tablet 2 times a day).
The maximum daily dose makes 900 mg (on 1 tablet 3 times a day).
Side effects
- nausea
- urticaria
- face reddening
- a headache
- swelling and an abdominal pain
of the Contraindication
- hypersensitivity to drug components
- a peptic ulcer of a stomach and duodenum, chronic
gastritis (in an aggravation phase)
- children's and teenage age up to 18 years
- pregnancy and the period of a lactation
Medicinal interactions
Strengthens effect of ascorbic acid on structure and permeability of a vascular wall.
Special indications
of Feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
Considering side effects of medicine it is necessary to be careful when driving or potentially dangerous mechanisms.
Overdose
Symptoms - strengthening of side effects of drug.
Treatment is symptomatic.
A form of release and packing
On 10 tablets in blister strip packaging from a film of polyvinylchloride and aluminum foil.
On the 3rd blister strip packagings together with the instruction for medical use on state and Russian place in a pack from cardboard.
To Store storage conditions in the dry place, at a temperature not above 25ºС.
To store out of children's reach.
Not to apply a period of storage of 5 years after an expiration date.
Prescription status
According to the prescription
the Producer
the Owner of a trademark and the certificate of registration is
the ROTAFARM company, Great Britain
KLEVA S.A Is made., Parnitos 189 Ave., 13671 Athens, Greece
According to the license AKARPIA of Servikos Pharmatseutikos of LDA, Portugal.
The address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products
of RK, Almaty, Turksibsky district, Suyunbaya Ave., 222b
Ph. / fax: 8 (7272) 529090
www.worldmedicine.kz
Related Products
Rompharm Company SRL for ROTAPHARM, UK (Romania)
Ripronat (Meldonium) 250 mg (40 capsules)
$17.00
Out Of Stock
